Hugo Vanderstichele

发表

Improving analytical performance of immunoassay methods

Michael Figurski, Teresa Waligorska, Hugo Vanderstichele, 2013, Alzheimer's & Dementia.

Machine learning for comprehensive forecasting of Alzheimer’s Disease progression

Jonathan R. Walsh, Aaron M. Smith, Charles K. Fisher, 2018, Scientific Reports.

Cerebrospinal fluid τ and β-amyloid(1-42) in dementia disorders

Kaj Blennow, Hugo Vanderstichele, Lennart Minthon, 2001, Mechanisms of Ageing and Development.

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

Hugo Vanderstichele, Wim Annaert, H. Vanderstichele, 1998, Nature.

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Leslie M. Shaw, Kaj Blennow, Hugo Vanderstichele, 2012, Alzheimer's & Dementia.

Accelerating drug development for Alzheimer's disease through the use of data standards

Jon Neville, Klaus Romero, Hugo Vanderstichele, 2017, Alzheimer's & dementia.

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.

Anders Wallin, Annika Olsson, Kaj Blennow, 2005, Clinical chemistry.

Neurofilament ELISA validation.

Bernhard Hemmer, Gavin Giovannoni, Johannes Kornhuber, 2010, Journal of immunological methods.

Amino-Truncated β-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment

Anders Wallin, Annika Olsson, Kaj Blennow, 2005 .

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

Katharina Buerger, Harald Hampel, Kaj Blennow, 2004, Archives of general psychiatry.

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

Robert A. Dean, Leslie M. Shaw, John Q. Trojanowski, 2011, Acta Neuropathologica.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

Kevin Mills, Henrik Zetterberg, Niklas Mattsson, 2012, Biomarkers in medicine.

The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

Michael W. Weiner, Andrew J. Saykin, Robert A. Dean, 2015, Alzheimer's & Dementia.

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

Giovanni B. Frisoni, José Luis Molinuevo, Aase Handberg, 2011, Alzheimer's & Dementia.

Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study

Meike W. Vernooij, Frank J. Wolters, M. Arfan Ikram, 2018, Alzheimer's Research & Therapy.

Cerebrospinal fluid levels of total‐tau, phospho‐tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

Kaj Blennow, Hugo Vanderstichele, Eugeen Vanmechelen, 2003 .

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Harald Hampel, Wiesje M van der Flier, Philip Scheltens, 2015, Brain : a journal of neurology.

Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

Anders Wallin, Henrik Zetterberg, Kaj Blennow, 2010, Neurobiology of Aging.

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Magda Tsolaki, José Luis Molinuevo, Enrica Cavedo, 2015, Nature Reviews Neurology.

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Anders Wallin, Björn Holmberg, Annika Olsson, 2005, Clinical chemistry.

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Kaj Blennow, Hugo Vanderstichele, Eugeen Vanmechelen, 2003, Acta neurologica Scandinavica. Supplementum.